For condition: Arthritis
For condition: Psoriasis
For condition: Psoriatic Arthritis
Active Psoriatic Arthritis Research Trial (60 Weeks)
Study Summary
Who Can Participate?
Adults aged 18 years or older with psoriatic arthritis (PsA) may be eligible to participate.
Inclusion Criteria:
-
-
- Signs and symptoms consistent with PsA for at least 3 months
- Active arthritis as shown by a minimum of ≥ 3 tender joints and ≥ 3 swollen joints
- At least 1 active lesion of plaque psoriasis ≥ 2 cm in diameter, or any nail or nail bed changes characteristic of psoriasis
- Have had at least one of the following:
-
- inadequate response to an NSAID after a minimum of 2 weeks of therapy, OR
- inadequate response to a csDMARD and/or apremilast after a minimum of 12 consecutive weeks of therapy, or intolerance to a csDMARD and/or apremilast, OR
- inadequate response to up to 2 biologic DMARDs (up to 2 TNFi OR up to 2 IL-17i) after a minimum of 12 consecutive weeks of therapy, or intolerance to up to 2 biologic DMARDs
-
-
Participant Info:
-
-
- No cost to participate or receive treatment
- Regular visits with study doctors who specialise in treating psoriatic arthritis
- Will receive investigational oral treatment (active study drug) or placebo, during the placebo-controlled period
- Reimbursement for study-related expenses may be provided
-
How Long Will The Study Last?
-
-
- 60 weeks and involve about 14 visits to the study research site
-
For more information about this trial, please visit ClinicalTrials.gov
